Unfractionated versus fractionated heparin for percutaneous coronary intervention

Current Cardiology Reports

Volumn 4, Issue 4, 2002, Pages 327-333

  Arjomand, Heidar ^a   Surabhi, Satish K ^a   Cohen, Marc ^a  

^a HAHNEMANN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; FIBRINOGEN RECEPTOR; LOW MOLECULAR WEIGHT HEPARIN;

CORONARY ARTERY DISEASE; HUMAN; MULTIMODALITY CANCER THERAPY; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; COMBINED MODALITY THERAPY; CORONARY DISEASE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; TREATMENT OUTCOME;

EID: 0036653069     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-002-0069-6     Document Type: Review

References (50)

1. Gruntzig AR, Senning A, Siegenthaler WE: Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979, 301:61-68.
2. Popma JJ, Ohman M, Weitz J, et al.: Antithrombotic therapy in patients undergoing percutaneous coronary intervention. Chest 2001, 119:321S-336S.
3. Weitz JI: Low-molecular-weight heparins. N Engl J Med 1997, 337:688-698.
4. Cohen M: The role of low-molecular-weight heparin in the management of acute coronary syndromes. Curr Opin Cardiol 2001, 16:384-389.
5. Montalescot G, Cohen M: Low molecular weight heparins in the cardiac catheterization laboratory. J Thromb Thrombolysis 1999, 7:319-323.
6. Deutsch E, Cohen M, Radley DR, Tarazona N, Fromell GJ: Safety and efficacy of percutaneous procedures in patients receiving subcutaneous enoxaparin for unstable angina: Results of the ESSENCE trial. Circulation 1998, 98(Suppl I):563.
7. Collet JP, Montalescot G, Lison L, et al.: Percutaneous coronary intervention after subcutaneous enoxaparin pre-treatment in patients with unstable angina pectoris. Circulation 2001, 1035:658-663. safety and efficacy of enoxaparin use in patients requiring PCI.
8. Collet JP: Pharmacokinetic study of enoxaparin in patients undergoing percutaneous coronary intervention 8 to 12 hours after subcutaneous injection: the results of the PEPCI trial. From the proceedings of the American Heart Association Meeting; Anaheim, CA: November 2001.
9. Karsch KR, Preisack MB, Baildon R, et al.: Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty: Results of a randomized, double-blind, unfractionated heparin and placebo-controlled multicenter trial (REDUCE trial). J Am Coll Cardiol 1996, 28:1437-1443.
10. Rabah MM, Premmereur J, Graham M, et al.: Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol 1999, 84:1391-1395.
11. Kereiakes DJ, Grines C, Fry E, et al.: Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J Invasive Cardiol 2001, 13:272-278. NICE 1 and 4 data: enoxaparin with or without abciximab appears to provide safe and effective anticoagulation in patients proceeding to PCI.
12. Choussat R, Montalescot G, Collet JP, et al.: Low dose intravenous enoxaparin in elective percutaneous coronary intervention. Circulation 2001, 104(Suppl II):II-706.
13. Zidar JP: Low molecular weight heparin in coronary stenting. Can J Cardiol 1998, 14(Suppl E): 35E-39E.
14. Ferguson JJ, Antman EM, Bates ER, et al., for the NICE 3 investigators: The use of enoxaparin and IIb/IIIa antagonists in acute coronary syndromes, including PCI: Final results of the NICE 3 study. J Am Coll Cardiol 2001, 37(Suppl A): 365A.
15. Madan M, Radhakrishnan S, Pang JT, et al.: Optimal anticoagulation and platelet inhibition are achieved when enoxaparin is combined with small molecule glycoprotein IIb/IIIa inhibition during elective percutaneous coronary intervention. Circulation 2001, 104(Suppl II): II-385.
16. Bhatt DL, Lincoff AM, on the behalf of the CRUISE investigators: Combined use of eptifibatide and enoxaparin in elective percutaneous coronary intervention: the results of the CRUISE trial. Circulation 2001, 104(Suppl II): II-384.
17. Kereiakes DJ, Kleiman NS, Fry E, et al.: Dalteparin in combination with abciximab during percutaneous coronary intervention. Am Heart J 2001, 141:348-352.
18. Hirsch J: Heparin. N Engl J Med 1991, 324:1565-1574.
19. Bowers J, Ferguson JJ: The use of activated clotting time to monitor heparin therapy during and after interventional procedures. Clin Cardiol 1994, 17:357-361.
20. Avendano A, Ferguson JJ: Comparison of Hemochron and HemoTec activated clotting time target values during percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994, 23:907-910.
21. Ferguson JJ, Waly HM, Le D, Tomakov N, Wilson JM: The effect of body weight and body surface area correction of the distribution of the ACT response to bolus doses of heparin for PTCA. J Invas Cardiol. 1998, 10:318-322.
22. Neuenschwander C, Attenhofer C, Kiowski W, et al.: Activated clotting times and heparin need during coronary angioplasty in acute myocardial infarction and angina pectoris. Circulation 1993, 88:I-1107.
23. Ferguson JJ, Dougherty KG, Gaos CM, Bush HS, et al.: Relationship between procedural activated clotting time and outcome after percutaneous transluminal angioplasty. J Am Coll Cardiol 1994, 23:1061-1065.
24. Narins CR, Hillegass WB, Nelson CL, et al.: Relationship between activated clotting time during angioplasty and abrupt closure. Circulation 1996, 93:667-671.
25. Vainer J, Fleisch M, Gunnes P, et al.: Low dose heparin for routine angioplasty and stenting. Am J Cardiol 1996, 78:964-966.
26. Koch KT, Piek JJ, de Winter RJ, et al.: Safety of low dose heparin in elective coronary angioplasty. Heart 1997, 77:517-522.
27. Kaluski E, Krakover R, Cotter G, et al.: Minimal heparinization in coronary angioplasty-how much heparin is really warranted? Am J Cardiol 2000, 85:953-956.
28. Smith SJ, Dove JT, Jacobs AK, et al.: ACC/AHA guidelines for percutaneous coronary intervention: executive summary and recommendations: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee to revise the 1993 guidelines for Percutaneous Transluminal Coronary Angioplasty). Circulation 2001, 103:3019-3041.
29. Chew DP, Bhatt DL, Lincoff MA, et al.: Defining the optimal activated clotting time during percutaneous coronary intervention. Aggregate results from 6 randomized, controlled trials. Circulation 2001, 103:961-966.
30. Ellis SG, Roubin GS, Wilentz J, et al.: Effect of 18-to-24 hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J 1989, 117:777-782.
31. Friedman HZ, Cragg DR, Glazier SM, et al.: Randomized prospective evaluation of prolonged versus abbreviated intravenous heparin therapy after coronary angioplasty. J Am Coll Cardiol 1994, 24:1214.
32. Colombo A, Hall P, Nakamuta S, et al.: Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995, 91:1676-1688.
33. The EPIC investigators: Use of a monoclonal antibody directed against the glycoprotein IIb/IIIa receptor in highrisk coronary angioplasty: the EPIC investigation. N Engl J Med 1994, 330:956-961.
34. The EPILOG investigators: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization: the EPILOG investigators. N Engl J Med 1997, 336:1689-1696.
35. Lincoff AM, Califf RM, Moliterno DJ, et al.: Complimentary clinical benefits of coronary artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors: Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med 1999, 341:319-327.
36. The ESPRIT Investigators: Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized, placebo-controlled trial. Lancet 2000, 356:2037-2044.
37. Topol EJ, Moliterno DJ, Hermann HC, et al.: Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001, 344:1888-1894.
38. Kleiman NS, Lincoff MA, Kereiakes DJ, et al.: Diabetes Mellitus, Glycoprotein IIb/IIIa blockade, and heparin. Evidence for a complex interaction in a multicenter trial. Circulation 1998, 97:1912-1920.
39. Bull BS, Korpman RA, Huse WM, Briggs BD: Heparin therapy during extracorporeal circulation: I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg 1975, 69:674-684.
40. Young JA, Kisker TC, Doty DB: Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. Ann Thorac Surg 1978, 26:231-240.
41. Cohen M, Demers C, Gurfinkel EP, et al.: A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events Study Group. N Engl J Med 1997, 337:447-452.
42. Antman EM, McCabe CH, Gurfinkel EP, et al.: Enoxaparin prevents death and cardiac ischemic events in unstable angina/ Non-Q-wave myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial. Circulation 1999, 100:1593-1601.
43. Antman EM, Cohen M, Radley D, et al.: Assessment of the treatment effect of enoxaparin for unstable angina/non-Qwave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation 1999, 100:1602-1608.
44. Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group. Low molecular weight heparin during instability in coronary artery disease. Lancet 1996, 347:561-568.
45. FRagmin and Fast Revascularization during InStability in Coronary artery disease Investigators: Long-term low-molecularmass heparin in unstable coronary-artery disease: FRISC II prospective randomized multicenter study. Lancet 1999, 354:701-707.
46. Klein W, Buchwald A, Hillis SE, et al.: Comparison of low molecular weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation 1997, 96:61-68.
47. The FRAXIS Study Group: Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAXIS (Fraxiparine in Acute Ischemic Syndrome). Eur Heart J 1999, 20:1553-1562.
48. Goodman SG, Cohen M, Bigonzi F, et al.: Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: oneyear results of the ESSENCE study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. J Am Coll Cardiol 2000, 36:693-698.
49. Batchelor WB, Mahaffey KW, Berger PB, et al., on behalf of the ATLAST trial investigators: A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: The ATLAST trial. J Am Coll Cardiol 2002, 38:1608-1613.
50. Ferguson JJ: The design of the SYNERGY (Superior Yield of New Strategy of Enoxaparin, Revascularization, and Glycoprotein IIb/IIIa Inhibition) trial. From proceedings of the American Heart Association Meeting; Anaheim, CA: November 2001.